2-甲氧基-1-乙基磺酰氯 | 51517-01-2

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 磺酰卤
• 中文名称: 2-甲氧基-1-乙基磺酰氯
• 中文别名: 2-甲氧基乙烷磺酰氯
• 英文名称: 2-methoxyethane-1-sulfonyl chloride
• 英文别名: 2-methoxyethanesulfonyl chloride；2-methoxy-1-ethanesulfonyl chloride；2-methoxyethylsulfonyl chloride；2-methoxy-1-ethylsulfonyl chloride
• CAS: 51517-01-2
• 化学式: C₃H₇ClO₃S
• mdl: MFCD10032391
• 分子量: 158.606
• InChiKey: DUNNNVSEUCJEOY-UHFFFAOYSA-N

物化性质

• 沸点：
  192℃
• 密度：
  1.357
• 闪点：
  70℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2909199090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P261,P280,P305+P351+P338,P310
• 危险品运输编号：
  1760
• 危险性描述：
  H302,H314
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methoxy-1-ethanesulfonyl chloride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methoxy-1-ethanesulfonyl chloride
CAS number: 51517-01-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H7ClO3S
Molecular weight: 158.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲氧基-1-乙基磺酰氯 在 ammonium hydroxide 作用下， 以 水 为溶剂， 反应 5.0h， 以8%的产率得到2-methoxyethanesulfonamide
  参考文献：
  名称：

  THIAZOLIDINONE COMPOUNDS AND USE THEREOF

  摘要：

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。

  公开号：

  US20170253569A1
• 作为产物：
  描述：

  2-溴乙基甲基醚 在 sodium thiosulfate 、 氯化亚砜 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 2-甲氧基-1-乙基磺酰氯
  参考文献：
  名称：

  一种二肽基肽酶-IV抑制剂

  摘要：

  本发明提供了通式(I)的氨基四氢吡喃类衍生物，其药学上可接受的盐、水合物、溶剂化物、立体异构体，及其制备方法和包含该类化合物的药物组合物。该类化合物能抑制二肽基肽酶IV(DPP-IV)的活性，可用于治疗与二肽基肽酶IV相关的疾病，特别是糖尿病的治疗。

  公开号：

  CN106543189A

文献信息

• Clean and Economic Synthesis of Alkanesulfonyl Chlorides from S-Alkyl Isothiourea Salts via Bleach Oxidative Chlorosulfonation
  作者：Jiaxi Xu、Zhanhui Yang、Bingnan Zhou

  DOI：10.1055/s-0033-1338567

  日期：——

  Abstract A simple procedure for clean and economic synthesis of alkanesulfonyl chlorides via bleach-mediated oxidative chlorosulfonation of S-alkyl isothiourea salts is disclosed. This procedure is environment- and worker-friendly with the advantages of readily accessible materials and reagents, simple and safe operations, easy purification without chromatography, and affords high yields of up to 99%

  摘要 公开了通过漂白介导的S-烷基异硫脲盐的氧化氯磺化来清洁和经济地合成烷烃磺酰氯的简单方法。该方法对环境和工人均有利，具有易于获得的材料和试剂，简单安全的操作，无需色谱法即可轻松纯化的优点，并提供高达99％的高收率。 公开了通过漂白介导的S-烷基异硫脲盐的氧化氯磺化来清洁和经济地合成烷烃磺酰氯的简单方法。该方法对环境和工人均有利，具有易于获得的材料和试剂，简单安全的操作，无需色谱法即可轻松纯化的优点，并提供高达99％的高收率。
• NOVEL INHIBITORS OF PROTEIN KINASES
  申请人：Princeton Drug Discovery, LLC

  公开号：US20170240545A1

  公开（公告）日：2017-08-24

  Protein kinases are regulators of cellular signaling and their functional dysregulation is common in carcinogenesis and many other disease states or disorders. The present invention relates to novel chemical entities that have biological activity to modulate mammalian protein kinase enzymes. In particular, compounds of the invention display potent inhibition of breast tumor related kinase (BRK).

  蛋白激酶是细胞信号传导的调节因子，它们的功能失调在癌症发生和许多其他疾病状态或疾病中很常见。本发明涉及具有生物活性以调节哺乳动物蛋白激酶酶的新型化合物。具体而言，本发明的化合物显示对乳腺肿瘤相关激酶（BRK）的强效抑制。
• [EN] TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS<br/>[FR] TÉTRAHYDROPYRIDOPYRIMIDINES ET TÉTRAHYDROPYRIDOPYRIDINES COMME INHIBITEURS D'AG HBS (ANTIGÈNE DE SURFACE DU VIRUS DE L'HÉPATITE B) ET PRODUCTION D'ADN DE VHB POUR LE TRAITEMENT D'INFECTIONS PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016177655A1

  公开（公告）日：2016-11-10

  The present invention provides tetrahydropyridopyrimidines and tetrahydropyridopyridines having the general formula (I) wherein R1, R2, U, W, X, Y and Z are as described herein, as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment and prophylaxis of hepatitis B virus infections.

  本发明提供了具有一般式(I)的四氢吡啶嘧啶和四氢吡啶吡啶，其中R1、R2、U、W、X、Y和Z如本文所述，作为乙型肝炎病毒表面抗原（HBsAg）和HBV DNA的抑制剂，用于治疗和预防乙型肝炎病毒感染。
• [EN] 4-SUBSTITUTED PYRANO[3,4,B]PYRAZINE KAPPA AGONISTS FOR TREATING DRUG DEPENDENCY<br/>[FR] AGONISTES PYRANO [3,4,B] PYRAZINE KAPPA 4-SUBSTITUÉS POUR LE TRAITEMENT DE LA PHARMACODÉPENDANCE
  申请人：UNIV ROCKEFELLER

  公开号：WO2020247599A1

  公开（公告）日：2020-12-10

  1-Phenylacetyl-8-aminohexahydro-2H-pyrano[3,4-b]pyrazines of formula I are disclosed. The compounds are kappa ligands and are useful to treat drug dependency.

  公开了化学式I的1-苯乙酰基-8-氨基六氢-2H-吡喃并[3,4-b]吡嗪。这些化合物是kappa配体，可用于治疗药物依赖。
• [EN] ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES D'ARYLMÉTHYLÈNE UTILISÉS EN TANT QUE BLOQUEURS DES CANAUX POTASSIQUES KV1.3 DE TYPE SHAKER
  申请人：DE SHAW RES LLC

  公开号：WO2021071806A1

  公开（公告）日：2021-04-15

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

  描述了化合物的公式（I）或其药学上可接受的盐，其中取代基如本文所定义。还描述了包含相同化合物的药物组合物以及使用该药物的方法。